AMENDMENTS TO THE SPECIFICATION:

Please add the following new paragraph after the title on page 1, line 3:

This application is a divisional of U.S. Application Serial No. 10/196,362, filed on July 17, 2002, which is a divisional of U.S. Application Serial No. 09/043,563, filed on March 20, 1998, now U.S. Patent No. 6,455,549 issued on September 24, 2002, which was a national stage filing under 35 U.S.C. § 371 of International Application No. PCT/JP97/02531, filed on July 22, 1997; the entire contents of each application are incorporated by reference herein.

Please replace Table I (continued), on page 41, with the following amended Table I (continued):

Table I (continued)

Compound No.	Chemical Structure	Property	IR($CHCl_3$)	^{1}H-NMR($CDCl_3$)
13		Pale yellow crystal	2948, 2840 1702, 1600 1486, 1438 1364, 1320 1132, 1017	1.78(2H,m), 2.07(2H,m), 2.97-3.01(2H,m), 3.15(2H,m), 7.31- 7.35(1H,m), 7.59- 7.60(6H,m)
14		Oily substance	2949, 1702 1589, 1507 1490, 1320 1170, 1132 1014	1.76(2H,m), 2.02(2H,m), 2.96-2.99(2H,m), 3.12(2H,m), 7.00(4H,dd), 7.10(1H,t), 7.33(2H,t), 7.46(2H,d)
15		Colorless crystal	2949, 2842 1709, 1603 1508, 1438 1320, 1157 1131, 1018	1.72(2H,m), 2.00(2H,m), 2.93-2.96(2H,m), 3.11(2H,m), 3.94(2H,s), 6.96(2H,dd), 7.12- 7.16(4H,m), 7.42(2H,d)
16		Pale yellow crystal	3020, 2949 1706, 1603 1499, 1194 1169, 1131 1090, 1013	1.73-1.77(2H,m), 1.98- 2.05(2H,m), 2.96- 2.99(2H,m), 3.08- 3.15(2H,m), 6.93.- 7.05(6H,m), 7.46(2H,d)

Please replace Table I (continued) on Page 49 with the following amended Table I (continued):

Table I (continued)

Compound No.	Chemical Structure	Property Melting Point (Recrystalization solvent)	IR(KBr)	^{1}H-NMR($CDCl_3$)	Elementary analysis
44		Colorless crystal (1/2 fumarate) 215-216°C (methanol/ether)	(1/2 fumarate) 1571, 1488 1450, 1363 1230, 1099 1065, 1044 984	1.86(2H,m), 2.17-2.30(2H,m), 2.52-2.67(3H,m), 2.74-2.77(1H,m), 2.87(1H,m), 3.08-3.11(1H,m), 4.79(1H,dd), 2.76-2.30(1H,m), 2.33(7H,m), 7.58-7.63(6H,m)	$C_{27}H_{29}NO_4 \cdot 3/4H_2O$ (1/2 fumarate) C H N Calcd: 72.87 6.57 3.15 Found: 72.87 6.65 3.14

45		Colorless crystal (1/2 fumarate) 161-162°C (methanol/ether) $[\alpha]_D$ -7.03° (C=1.30, MeOH)	(1/2 fumarate) 1588, 1490 1367, 1292 1240, 1172 1106, 1079 1043, 984	1.55-1.83(2H,m), 2.08-2.22(2H,m), 2.55(1H,m), 2.63(2H,d), 2.78-2.85(2H,m), 2.91-2.94(1H,m), 4.01(2H,d), 4.14(1H,m), 6.93-7.02(7H,m), 7.10(1H,t), 7.26-7.36(4H,m), 7.46(2H,ddd)	$C_{28}H_{31}NO_6 \cdot 1/2H_2O$ (1/2 fumarate) C H N Calcd: 69.12 6.42 2.88 Found: 69.04 6.48 2.88
46		Colorless crystal (fumarate) 160-162°C (methanol/ether) $[\alpha]_D$ +7.03° (C=1.13, MeOH)	(fumarate) 1588, 1508 1490, 1372 1292, 1243 1172, 1044 984	1.81(2H,m), 2.15(2H,m), 2.54(1H,dt), 3.45(2H,d), 2.78-2.86(2H,m) 2.93(1H,m), 4.01(2H,d), 4.14(1H,m), 6.93-7.03(7H,m), 7.11(1H,t), 7.26-7.36(4H,m), 7.47(2H,d)	$C_{28}H_{31}NO_6 \cdot 3/4H_2O$ (1/2 fumarate) C H N Calcd: 68.49 6.36 2.85 Found: 68.74 6.41 2.90
47		Colorless crystal (1/2 fumarate) 178-180°C (methanol/ether) $[\alpha]_D$ -7.96° (C=1.07, MeOH)	(1/2 fumarate) 1600, 1570 1508, 1368 1247, 1222 1096, 1045 985	1.77-1.80(2H,m), 2.14(2H,m), 2.54(1H,m), 2.62(2H,d), 2.77-2.85(2H,m), 2.90-2.93(1H,m), 3.94(2H,s), 4.00(2H,dd), 4.11-4.16(1H,m), 6.92-6.99(5H,m), 7.12-7.17(4H,m), 7.26-7.30(2H,m), 7.42(2H,d)	$C_{29}H_{32}FNO_5$ (1/2 fumarate) C H N Calcd: 70.57 6.53 2.84 Found: 70.28 6.59 2.84

Please replace the paragraph on page 54, beginning on line 1 and ending on page 54, line 11 with the following amended paragraph as follows:

Inhibitory Effect of Veratridine-induced sodium channel activity

The membrane potential of the synaptozomes prepared from the brain membrane of Wistar rats (male, 10 to 12 weeks old) was measured by the method of Aiuchi et al. (t. Aiuchi et al: Biochimi. Biophys. Acta. 771, 228 (1984)) using a membrane potential sensitive fluorescent dye Rhodamine 6G to evaluate the effects of suppression of the compound on the veratridine-inducing depolarization response. The results are shown in Table II.

Please replace the portion of Table II on page 54 as follows:

Compound No.	Anti-veratridine effect (inhibiting rate %) (compound 0.1 μM)
17	26.8
18	13.1
19	12.9
20	20.2
21	18.6
23	11.3
24	23.8
25	57
26	30
27	41
28	24
29	40
31	14
32	27.3
33	12.8
34	29.9
35	27.7